TY - JOUR
T1 - Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel
AU - Caers, J.
AU - Paiva, B.
AU - Zamagni, E.
AU - Leleu, X.
AU - Bladé, J.
AU - Kristinsson, S. Y.
AU - Touzeau, C.
AU - Abildgaard, N.
AU - Terpos, E.
AU - Heusschen, R.
AU - Ocio, E.
AU - Delforge, M.
AU - Sezer, O.
AU - Beksac, M.
AU - Ludwig, H.
AU - Merlini, G.
AU - Moreau, P.
AU - Zweegman, S.
AU - Engelhardt, M.
AU - Rosiñol, L.
PY - 2018
Y1 - 2018
N2 - Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography-computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For decades, treatment has been based on high-dose radiation, but studies exploring the potential benefit of systemic therapies for high-risk patients are urgently needed. In this review, a panel of expert European hematologists updates the recommendations on the diagnosis and management of patients with solitary plasmacytoma.
AB - Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography-computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For decades, treatment has been based on high-dose radiation, but studies exploring the potential benefit of systemic therapies for high-risk patients are urgently needed. In this review, a panel of expert European hematologists updates the recommendations on the diagnosis and management of patients with solitary plasmacytoma.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85040833274&origin=inward
U2 - https://doi.org/10.1186/s13045-017-0549-1
DO - https://doi.org/10.1186/s13045-017-0549-1
M3 - Review article
C2 - 29338789
SN - 1756-8722
VL - 11
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
IS - 1
M1 - 10
ER -